Stryker Co. (NYSE:SYK) Position Reduced by AHL Investment Management Inc.

AHL Investment Management Inc. lowered its holdings in Stryker Co. (NYSE:SYK) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,880 shares of the medical technology company’s stock after selling 225 shares during the period. Stryker makes up 3.2% of AHL Investment Management Inc.’s portfolio, making the stock its 9th biggest position. AHL Investment Management Inc.’s holdings in Stryker were worth $4,637,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Trueblood Wealth Management LLC raised its position in Stryker by 10.5% in the fourth quarter. Trueblood Wealth Management LLC now owns 3,140 shares of the medical technology company’s stock valued at $1,131,000 after purchasing an additional 299 shares during the period. Diversify Wealth Management LLC grew its position in Stryker by 4.2% in the fourth quarter. Diversify Wealth Management LLC now owns 9,205 shares of the medical technology company’s stock valued at $3,366,000 after acquiring an additional 373 shares in the last quarter. Terra Nova Asset Management LLC lifted its position in shares of Stryker by 0.4% during the fourth quarter. Terra Nova Asset Management LLC now owns 8,344 shares of the medical technology company’s stock worth $3,004,000 after purchasing an additional 32 shares in the last quarter. Annex Advisory Services LLC increased its position in shares of Stryker by 63.0% during the fourth quarter. Annex Advisory Services LLC now owns 13,549 shares of the medical technology company’s stock worth $4,878,000 after acquiring an additional 5,235 shares during the last quarter. Finally, Grove Bank & Trust boosted its holdings in Stryker by 43.4% in the fourth quarter. Grove Bank & Trust now owns 175 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 53 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 0.6 %

Stryker stock opened at $383.91 on Monday. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91. The firm has a market cap of $146.35 billion, a PE ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95. The firm’s 50 day moving average price is $375.51 and its two-hundred day moving average price is $358.98.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 earnings per share. On average, research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Tuesday, December 31st. This is an increase from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is 36.01%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Evercore ISI boosted their target price on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Barclays lifted their price objective on shares of Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a report on Thursday, October 31st. Wells Fargo & Company raised their price target on shares of Stryker from $405.00 to $427.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Finally, Truist Financial increased their price objective on shares of Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.

Insider Activity at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.50% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.